-
公开(公告)号:US20240059687A1
公开(公告)日:2024-02-22
申请号:US18451465
申请日:2023-08-17
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
公开(公告)号:US20220064169A1
公开(公告)日:2022-03-03
申请号:US17288225
申请日:2019-10-23
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG
IPC: C07D487/04
Abstract: The present disclosure relates to novel PDE2 inhibitory compounds of Formula I as described herein, their use as pharmaceuticals and pharmaceutical compositions comprising them.
-
公开(公告)号:US20170360792A1
公开(公告)日:2017-12-21
申请号:US15533527
申请日:2015-12-07
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Gretchen SNYDER , Lawrence P. WENNOGLE , Joseph HENDRICK
IPC: A61K31/519 , C07D231/06 , C07D231/54 , C07D487/04 , C07D403/14
CPC classification number: A61K31/519 , A61K2300/00 , C07D231/06 , C07D231/54 , C07D403/14 , C07D487/04
Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.
-
公开(公告)号:US20210163481A1
公开(公告)日:2021-06-03
申请号:US16634059
申请日:2018-07-20
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
公开(公告)号:US20170360753A1
公开(公告)日:2017-12-21
申请号:US15533525
申请日:2015-12-07
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Gretchen SNYDER , Lawrence P. WENNOGLE , Joseph HENDRICK
IPC: A61K31/4162 , C07D403/14 , C07D209/58 , C07D471/14
CPC classification number: A61K31/4162 , A61K2300/00 , C07D209/58 , C07D403/14 , C07D471/14
Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.
-
公开(公告)号:US20170291904A1
公开(公告)日:2017-10-12
申请号:US15512005
申请日:2015-09-17
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Jun ZHAO , Lawrence WENNOGLE
IPC: C07D487/14
CPC classification number: C07D487/14
Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
-
公开(公告)号:US20190000807A1
公开(公告)日:2019-01-03
申请号:US16125373
申请日:2018-09-07
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Gretchen SNYDER , Lawrence P. WENNOGLE , Joseph HENDRICK
IPC: A61K31/4162 , C07D403/14 , C07D209/58 , C07D471/14
Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.
-
公开(公告)号:US20170233399A1
公开(公告)日:2017-08-17
申请号:US15502464
申请日:2015-08-06
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor: Peng LI , Hailin ZHENG , Jun ZHAO , Lawrence P. WENNOGLE
IPC: C07D487/14 , A61K45/06 , A61K31/519
CPC classification number: C07D487/14 , A61K31/519 , A61K45/06
Abstract: The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
-
公开(公告)号:US20170226117A1
公开(公告)日:2017-08-10
申请号:US15502144
申请日:2015-08-07
Applicant: Intra-Cellular Therapies, Inc.
Inventor: Peng LI , Hailin ZHENG , Jun Zhao , Lawrence P. Wennogle
IPC: C07D487/14 , A61K31/519 , A61K45/06
CPC classification number: C07D487/14 , A61K31/519 , A61K45/06 , A61K2300/00
Abstract: The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
-
公开(公告)号:US20150072965A1
公开(公告)日:2015-03-12
申请号:US14539859
申请日:2014-11-12
Applicant: Intra-Cellular Therapies, Inc.
Inventor: Peng LI , Jun ZHAO , Hailin ZHENG , Lawrence WENNOGLE
IPC: C07D487/14 , A61K45/06 , A61K31/165 , A61K31/519
CPC classification number: C07D487/14 , A61K31/165 , A61K31/519 , A61K31/5365 , A61K45/06
Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.
Abstract translation: 任选取代的4,5,7,8-四氢 - (任选4-氧代,4-硫代或4-亚氨基)-2H-咪唑并[1,2-a]吡咯并[3,4-e]嘧啶或4,5 ,7,8,9-五氢 - (任选4-氧代,4-硫代或4-亚氨基)-2H-嘧啶并[1,2-a]吡咯并[3,4-e]嘧啶化合物或式 ),其生产方法,它们作为药物的用途和包含其的药物组合物。
-
-
-
-
-
-
-
-
-